European Commission approves obicetrapib, a CETP inhibitor for hypercholesterolemia, offering oral dosing and 41% LDL-C reduction in Phase 3 trials.
The FDA has granted Priority Review to Alexion's BLA for efzimfotase alfa, a biweekly enzyme replacement therapy for hypophosphatasia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results